APP Pharmaceuticals Announces Approval of Clonidine Hydrochloride Injection

APP Pharmaceuticals announced that it has received approval from the FDA to market clonidine hydrochloride injection in two dosage strengths. Clonidine hydrochloride injection is therapeutically equivalent to the reference-listed drug Duraclon.
BusinessWire